Europe Facial Injectable Market is projected to reach USD 3.70 billion by 2029
In 2021, the market for facial injectables in Europe was estimated to be worth USD 2.20 billion. The market is anticipated to increase by 4.1% CAGR from 2022 to 2029, rising from USD 2.80 billion in 2022 to USD 3.70 billion in 2029. The COVID-19 pandemic has been unprecedented and shocking, with demand across all regions being lower than expected compared to pre-pandemic levels. According to our research, the market for facial injectables in Europe experienced a decline of 21.9% in 2020 compared to 2019.
Access Full Reports: https://www.fortunebusinessinsights.com/europe-facial-injectable-market-106778
The Europe facial injectable market report offers a thorough analysis of the market and focuses on important issues like pricing analysis, significant business transactions like mergers, partnerships, and acquisitions, new product launches, significant market trends, the effect of COVID-19 on the European market, the share of facial injectables in overall non-surgical procedures in the EU5 countries, and expert insights. In addition to these, the report highlights key strategies used by key players and provides market forecast insights into opportunities. The report includes a number of additional factors in addition to those mentioned above that have assisted in the market’s expansion in recent years.
Key Development:
October 2020: Luminera, a privately-held aesthetics business located in Israel with a portfolio and pipeline of dermal filler treatments, was acquired by Allergan Aesthetics, a division of AbbVie, Inc.
Driving Factor:
Rising Number of Nonsurgical Injectable Treatments to Strengthen Growth
Aesthetic treatments have become more popular among people of all ages, including children and the elderly. Additionally, the increased safety features of these devices have led to their increased popularity. Therefore, boosting the facial injectables market share. According to the International Society of Aesthetic Plastic Surgery (ISAPS) figures, the total number of nonsurgical injectable treatments performed in India in 2019 was 113,616. Furthermore, nations such as the United States, France, Italy, and Germany saw significant increases in the number of face injectable treatments. According to the American Academy of Face Plastic and Reconstructive Surgery’s (AAFPRS) annual study, botulinum toxin and dermal fillers accounted for four-fifth of all treatments performed by facial surgeons in the United States in 2018.
Segmentation:
Based on type, the global market is classified into botulinum toxin, collagen, hyaluronic acid, calcium hydroxylapatite, polylactic acid, polymethyl-methacrylate microspheres (PMMA), fat injection, and others.
Based on application, the market is classified into wrinkle reduction, facelift, acne scar treatment, lipoatrophy treatment, lip enhancement, and others.
Based on end users, the market is segmented into hospitals & ambulatory surgery centres, dermatology and cosmetic clinics, and others. The hospitals & ambulatory surgery centers segment is expected to account for a significant share. According to the American Society of Plastic Surgeons (ASPS), in 2019, an estimated 25.0% of cosmetic procedures were performed in hospitals in the United States.
Geographically, the global Facial Injectables Market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
Ask for In-depth Report Sample: https://www.fortunebusinessinsights.com/enquiry/sample/europe-facial-injectable-market-106778
Regional Insights:
Increasing Aesthetic Plastic Surgery to Bolster Business in North America
North America’s market size was USD 2.14 billion in 2020, and the region is anticipated to be the largest during the forecast period. The strong demand for aesthetic procedures such as the administration of facial injectables industry coupled with the presence of key players in the region, such as ALLERGAN (AbbVie, Inc.), is expected to contribute to the growth in the region. For instance, according to the International Society of Aesthetic Plastic Surgery (ISAPS) statistics, in the United States, cosmetic botulinum toxin procedures amounted to 1,301,823 in 2019. In 2020, the European region was anticipated to account for the second-largest facial injectable market share. The high volume of cosmetic treatments in the region, such as botulinum toxin and dermal fillers, is one reason for the region’s perpetual growth.
Competitive Landscape:
ALLERGAN to Hold the Lion’s Share
ALLERGAN (AbbVie, Inc.) is the market leader in terms of the competitive landscape, owing to the company’s powerful face injectables portfolio, which includes dermal fillers and botulinum toxin for aesthetic treatments. JUVEDERM, the company’s dermal filler product line, dominates this market. JUVEDERM is a hyaluronic acid-based dermal filler used in various cosmetic treatments, including wrinkle reduction. ALLERGAN also sells BOTOX Cosmetic, which is a well-known product. JUVEDERM, the company’s dermal filler product line, dominates the facial injectables market trends. JUVEDERM is a hyaluronic acid-based dermal filler used in various cosmetic treatments, including wrinkle reduction. ALLERGAN also sells BOTOX Cosmetic, which is a well-known product.
Factors like rising consciousness about external appearance among young and old individuals and rising awareness regarding the availability of various products and procedures, attributed to increasing globalization and social media influence are projected to further fuel the facial injectable market growth.
The Report Lists the Key Players in the Facial Injectables Market:
- ALLERGAN (AbbVie, Inc.) (North Chicago, U.S.)
- Ipsen Pharma (Paris, France)
- USWM, LLC (US WorldMeds) (Louisville, U.S.)
- Revance Therapeutics, Inc. (Nashville, U.S.)
- Merz Pharma (Frankfurt, Germany)
- GALDERMA (Lausanne, Switzerland)
- Sinclair Pharma (London, U.K.)
- BIOPLUS CO., LTD. (Seongnam-si, South Korea)
- Bioxis pharmaceuticals (Lyon, France)
- Anika Therapeutics, Inc. (Bedford, U.S.)
